期刊
CLINICAL CANCER RESEARCH
卷 26, 期 22, 页码 5791-5800出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-1967
关键词
-
类别
资金
- Tier 1 Canada Research Chair in Molecular Oncology
- Canadian Institutes of Health Research (CIHR) [FRN: 142263]
- Terry Fox Research Institute [PPG-1064]
- Canadian Cancer Society [706394]
- Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program [W81XWH-16-1-0068]
- CIHR Doctoral Research award
- Princess Margaret Hospital Foundation Graduate Fellowship in Cancer Research
- George Knudson Memorial Fellowship
Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of evidence indicate that certain cancers depend on the mevalonate pathway for growth and survival, and, therefore, are vulnerable to statin therapy. However, these immediately available, well-tolerated, and inexpensive drugs have yet to be successfully repurposed and integrated into cancer patient care. In this review, we highlight recent advances and outline important considerations for advancing statins to clinical trials in oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据